Synovel Sciences Overview

  • Founded
  • 2014
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Synovel Sciences General Information


Developer of cancer eliminating drugs intended to offer cost effective alternatives to fulfill medical needs. The company's drugs are directed to eliminate cancer cells by specific modulation of immune checkpoint receptors.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Taipei
  • Taiwan
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Synovel Sciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 01-Mar-2017 000.00 Completed Generating Revenue
1. Early Stage VC 01-Jan-2015 000.00 000.00 Completed Startup
To view Synovel Sciences’s complete valuation and funding history, request access »

Synovel Sciences Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Diamond Capital (Taiwan) Venture Capital Minority 000 0000 000000 0
To view Synovel Sciences’s complete investors history, request access »